Buloxibutid (AT2 Agonist C21) is a selective agonist of angiotensin II type 2 receptor (AT2R) with a Ki value of 0.4 nM for the AT2 receptor and a Ki >10 µM for the AT1 receptor. Its treatment significantly reduces vascular remodelling, improves hemodynamics, and decreases pulmonary collagen deposition in the Sugen-Hypoxia model of pulmonary hypertension.

GLPG0187 is a broad-spectrum antagonist of integrin receptor. It inhibits αvβ1-integrin with an IC50 value of 1.3 nM. GLPG0187 also inhibits migrasome biogenesis without cytotoxicity. GLPG0187 exhibits potent antitumor activity.

GLPG0187 is a broad-spectrum antagonist of integrin receptor. It inhibits αvβ1-integrin with an IC50 value of 1.3 nM. GLPG0187 also inhibits migrasome biogenesis without cytotoxicity. GLPG0187 exhibits potent antitumor activity.

GLPG0187 is a broad-spectrum antagonist of integrin receptor. It inhibits αvβ1-integrin with an IC50 value of 1.3 nM. GLPG0187 also inhibits migrasome biogenesis without cytotoxicity. GLPG0187 exhibits potent antitumor activity.

GLPG0187 is a broad-spectrum antagonist of integrin receptor. It inhibits αvβ1-integrin with an IC50 value of 1.3 nM. GLPG0187 also inhibits migrasome biogenesis without cytotoxicity. GLPG0187 exhibits potent antitumor activity.

Coelenterazine h (2-Deoxycoelenterazine, CLZN-h) is a luminophore derivative of coelenterazine, serves as a luminescent substrate for RLuc8. It enhances the sensitivity of recombinant aequorin to Ca²⁺, enabling the detection of subtle calcium changes in response to touch and wounding and making it a valuable tool for measuring small Ca²⁺ fluctuations.

iCARM1 (CARM1-IN-6) is a potent and selective inhibitor of protein arginine methyltransferase CARM1 (PRMT4) with an IC50 of 12.3 μM. It potently suppresses breast cancer cell growth both in vitro and in vivo and can be used in cancer research.

iCARM1 (CARM1-IN-6) is a potent and selective inhibitor of protein arginine methyltransferase CARM1 (PRMT4) with an IC50 of 12.3 μM. It potently suppresses breast cancer cell growth both in vitro and in vivo and can be used in cancer research.

iCARM1 (CARM1-IN-6) is a potent and selective inhibitor of protein arginine methyltransferase CARM1 (PRMT4) with an IC50 of 12.3 μM. It potently suppresses breast cancer cell growth both in vitro and in vivo and can be used in cancer research.

iCARM1 (CARM1-IN-6) is a potent and selective inhibitor of protein arginine methyltransferase CARM1 (PRMT4) with an IC50 of 12.3 μM. It potently suppresses breast cancer cell growth both in vitro and in vivo and can be used in cancer research.